Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
LEXINGTON, Mass., June 01, 2017 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that Ali Fattaey, Ph.D., President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 7, 2017, at 3 p.m. EDT in New York City.
A corresponding webcast of the presentation can be accessed by visiting:
http://www.wsw.com/webcast/jeff105/cris
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead candidate, CUDC-907 that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 and VISTA pathways, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis' website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
